Northland analyst Carl Byrnes named MiMedx as a “2024 Top Pick” and a “core holding for those investing in the healthcare sector.” The firm, which views the recent pullback as a buying opportunity and continues to see significant upside in FY24 and beyond, keeps an Outperform rating and $12 price target on MiMedx shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MDXG:
- MIMEDX Provides AXIOFILL® Update & Reiterates 2023 Full Year Net Sales and Fourth Quarter Adjusted EBITDA Margin Outlook
- MiMedx announces conversion of outstanding Series B convertible preferred stock
- MIMEDX Announces Conversion of Outstanding Series B Convertible Preferred Stock to Common Stock
- Spectral AI appoints Peter Carlson as CFO
- MIMEDX to Participate in Upcoming Investor Conferences
